NEW YORK – Mission Bio today announced a comarketing agreement for its Tapestri single-cell analysis platform with Agilent Technologies.
The deal will help bring Tapestri to cancer researchers in North America, Mission Bio said in a statement. The firms did not specify which Agilent products Tapestri will marketed together.
Financial and other details of the agreement were not disclosed. Agilent has been investing in South San Francisco-based Mission Bio since 2014 and co-led the firm's 2018 $30 million Series B financing round.